ESG Index
Our Sustainability Strategy
| Our approach is holistic and integrates the three dimensions of sustainability: society, environment and economy. | Our Approach to Sustainability |
| We have developed targets and are measuring performance to drive impact across our three focus areas: access to innovation, people and environment. | Sustainability targets and performance
Assurance of our Non-Financial Reporting: Annual Report p.156 - 161 |
| Our annual report contains extensive information on our approach to non-financial reporting and materiality. | Annual Report 2025 |
| Sustainability-related positions, policies & downloads | Our Sustainability Download Center |
| Science Based Targets Initiative (SBTI): Roche’s targets were approved by SBTi in 2025. | Climate Change |
| EcoVadis: In 2025, Roche has been awarded a Silver medal from EcoVadis sustainability rating agency, achieving a score of 69/100. This score places Roche in the top 15% of companies rated. | Ecovadis |
| In 2024, Roche has been ranked 11th out of 20 of the world's biggest pharmaceutical companies assessed | Access to Medicine Index Ranking |
| World Business Council for Sustainable Development: Roche has been a member since 1995 and is particularly active in the following projects: i) Circular Plastics & Packaging & ii) Partnership for Carbon Transparency Projects | World Business Council for Sustainable Development (WBCSD) |
| Biopharma Sustainability Roundtable: We are a founding member (2013) | Biopharma Sustainability Roundtable (BSRT) |
| The Capitals Coalition: Roche has been a member since 2016 | The Capitals Coalition |
| Sustainable Markets Initiative: We are a founding member (2021) and activley participate in the Health Systems Industry Taskforce | Sustainable Markets Initiative (SMI) |
| Value Balancing Alliance: Roche joined the Alliance in July 2021 | Value Balancing Alliance |
| Pharmaceutical Supply Chain Initiative: Roche is a founding member (2006) & Scope 3 Group Lead | Pharmaceutical Supply Chain Initiative (PSCI) |
| Roche is a sponsor of the Energize programme, which aims to increase access to renewable energy electricity for suppliers to the pharmaceutical industry | Energize programme |
Environmental
| Respect for a healthy planet and the environment has always been a priority of our founding families and the company. | Overview Environmental Sustainability 2023 Investor Event on Environmental Sustainability |
| 2029 target: We are committed to halving the environmental impact of our operations (eco-balance points) and products (product stewardship score) from a 2019 baseline | Our SHE Goals & Performance |
| SHE goals for the Roche Group: 2025 - 2029 | |
| Performance Sheet - Eco-balance |
| We are committed to achieving net zero carbon emissions by 2045 and have set near- and long-term targets validated by SBTi | Climate Change |
| Performance Sheet - GHG Emissions | |
| Performance Sheet - Scope 3 emissions | |
| Position on GHG and Climate Change |
| Particulate emissions, VOC, SO2, NOx | Performance Sheet - other emissions to air |
| 100% sustainable electricity throughout the 5-year target period 2029: 5% reduction in delivered energy per employee | Our SHE Goals & Performance |
| Performance Sheet - Energy consumption | |
| Position on Energy Conservation |
| Target: Minimise the environmental impact of products by 50% from 2020-2029 | Sustainable products |
| Position on Product Stewardship |
| Our commitment to sustainability stretches beyond our own business practices – it also includes ensuring our suppliers’ approach to sustainability aligns with Roche’s. | Sustainability in procurement practices |
| Resources and Raw Materials | |
| Position on SHE in the Supply Chain | |
| Supplier Code of Conduct |
| 2029: Reduce phosphorus emissions to wastewater by 64% | Performance Sheet - Use of water |
| 2029: Reduce the Roche risk-weighted water consumption by 5% | Performance Sheet - Emissions to Water |
| Position on Water | |
| Position on Pharmaceuticals in the Environment |
| Reduce total non-hazardous and hazardous waste generated by 5% | Recycling and Waste Management |
| Performance Sheet - Waste management and recycling | |
| Position on pollution prevention and reduction | |
| Position on waste management | |
| Position on circular economy | |
| Position on Landfills and Contaminated Soils |
| We support sustainable biological resource development by adhering to the broad principles espoused in the United Nations Convention on Biological Diversity (CBD) and further developed in the Nagoya Protocol. | Performance Sheet - Supporting Biodiversity |
| Position on Biodiversity |
Social
| We contribute to a better society by enabling the right treatment for the right patient at the right time for the right value. We do this by developing new medicines and ways of diagnosing disease and insights from data. | Overview Social Sustainability |
| Divisional access ambitions: Pharmaceuticals: Deliver 20 transformative medicines addressing diseases with the highest societal burden by 2030 Double patient numbers in LMICs for our innovative medicines by 2026 Diagnostics: Double patient access to novel, high medical value diagnostics solutions by 2030 | 2022 Investor Event on Access to Healthcare Ensuring early and accurate diagnosis Growing healthcare capacity Increasing disease awareness |
| Our pricing approach reflects the World Health Organization’s definition of “Fair Pricing”, balancing affordability and incentives for innovation; serving the needs of patients today and tomorrow | Position on Pricing |
| Roche works with suppliers and service providers to create, enhance and maintain sustainable value | Working with Suppliers |
| Sustainability Principles | |
| Supplier Code of Conduct | |
| Procurement Risk Management | |
| Improving the supply chain | |
| Suppliers Success Stories | |
| Position on SHE in the Supply Chain | |
| Human Rights in the value chain |
| Our people make our business and are at the heart of who we are. We prioritise employee safety, health and development, while encouraging a workplace environment that embraces integrity, mutual respect and opportunities for all. | People |
| Employment Policy | |
| Code of Conduct: Discrimination & Harassment | |
| Health and Safety KPIs | |
| Health and Safety Targets | |
| Incident management fact sheet |
| We respect and support the human rights of every person we reach and ensure they are rigorously embedded into every aspect of our business | Human Rights |
| Human Rights in the value chain | |
| Position Paper on Human Rights |
| Patients are at the core of what we do. This is why we partner with them at each stage of drug development and care delivery. | Patient partners |
| Working with Patient Organisations | |
| Clinical trials platform for patients |
| To ensure that every Roche product is both effective and safe, we have established a systematic process designed to optimise patient safety throughout the lifecycle of a medicine. | Drug Safety |
| Anti-Counterfeiting | |
| Patient safety | |
| Quality Standards & Good Practices |
| Our pledge to create positive and sustainable social value goes beyond healthcare. We are dedicated to making a lasting impact on society by building stronger and healthier communities. | Our Approach to Philanthropy |
Governance
| Roche is committed to serving all its stakeholders. Our Corporate Governance principles put the focus of our business activities on sustainable value creation and innovation and prescribe a management culture conforming to recognised standards of good corporate governance and a policy of transparent communication. | Governance Structure |
| Board of Directors | |
| Board Committees | |
| Executive Committee | |
| A performance- and success-based, transparent and market competitive remuneration is an important factor for a globally operating company like Roche. The bonus structure for employees and managers includes targets relating to societal and environmental objectives. | Remuneration Report 2025 |
| Annual General Meeting | |
| Articles of Incorporation and Bylaws | |
| Statutory Auditors | |
| Annual and Finance Reports |
| As sustainability is embedded into our business strategy, a strong commitment from all business areas, and from senior management, is reflected in the sustainability governance structure. | Our Sustainability Governance Structure |
| Our approach to materiality assessment is integrated - built on our Group Risk Management Process - and inclusive, as it is designed collaboratively across multiple functions. | Materiality Assessment |
| Stakeholder Engagement |
| By continuously engaging with policy makers, we ensure Roche creates long-term impact not only for patients, but society as a whole. | Our approach to public policy |
| Guidelines: Working with Government Officials |
| Position on Roche’s Approach to Tax | |
| Further information on income taxes and effective tax rates can be found in the Finance Reports | Annual and Finance Reports |
| Roche follows existing principles, regulations and guidelines to ensure the highest ethical standards in our research | Roche ethical standards in our research |
| Ethical Standards - Genetics | |
| Ethical standards - Scientific Ethics Advisory Group | |
| Roche conducts stem cell research, inhouse as well as in cooperation with external partners, to become technically enabled in this research area, and with the ultimate aim to develop treatment strategies for incurable or inadequately treated severe diseases. | Position on Human Stem Cells |
| Roche is pioneering and promoting innovative approaches in preclinical research to replace animal testing. | Ethical standards - Animal research Replacing animal testing |
| Business Ethics in supply chain |
| The Roche Group Code of Conduct states the expectations Roche has as an employer towards employees and sets forth the standards for business behaviour that apply throughout the Roche Group. | Code of Conduct Overview |
| Chief Compliance Officer | |
| Bribery, Improper advantages and corruption policy | Behavior in Business: Directive on Integrity in Business |
| Drug Promotion Standards and Ethical Marketing | Code of Conduct: Information & Marketing |
| Our Risk Management processes assess the possibility that an event will occur and adversely affect the achievement of objectives - these risks are identified, managed and if need be reported. | Risk Management |
| Risk Management Policy | |
| Group Business Continuity Management Policy | |
| The maintenance of high ethical standards in adhering to national and international laws is one of the fundamental Roche Corporate Principles. | Behaviour in Competition |
| Group Insider Directive | |
| Overview of significant legal cases | Finance Report 2025 p.95 - 97 |
| We are turning today’s understanding of disease biology, diagnosis, detection and treatment into tomorrow's solutions. Discover our promising pipeline. | Product pipeline |
| Partnering with biotechs | |
| Clinical trials are essential to determine whether new drugs or diagnostics are safe and effective when used to diagnose or treat people. | Clinical trial Programme and Standards |
| ClinicalTrials.gov research platform |
| We strongly believe that robust intellectual property systems stimulate innovation and economic growth for the benefit of society as a whole. | Code of Conduct : Intellectual Property Rights |
| Position on Intellectual Property | |
| Position on TRIPS and Doha Declaration |
| Roche’s Position on Access to & Use of Real World Data | |
| Roche shares clinical data because we understand it helps physicians, patients and healthcare providers to make informed treatment decisions. Data sharing can also enable researchers to more easily build on existing research in the hope of advancing scientific progress. | Our commitment to share clinical data |
| Roche Global Policy on Sharing of Clinical Study Information |